AzTrials
AzTrials

AgingNCT07373444

Westlake Aging Cohort (WeAC)

An observational study of Aging and Cognition Improvement, run by Westlake University at 2 sites in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. Read more about this study

Who is it for?
Ages 55 to 90 yearsHealthy volunteers can take part
Conditions the study is for
Aging, Cognition Improvement, Cognition Disorders
How many people
2,800 participants
Where
2 sitesChina
Study dates
1 Jan 2026to 31 Dec 2031
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: All participants must be Chinese residents, regardless of their ethnicity.

Who may be able to join

  • Age between 55 and 90 years (inclusive) at baseline.
  • Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
  • Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
  • MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
  • Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
  • Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.

Who cannot join

  • Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
  • Current use of psychoactive medications or any other drugs that may affect the study.
  • Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
  • Participants with any other diseases that may affect the study.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Ju-Sheng Zheng, PhD contact

86-0571-86915303

zhengjusheng@westlake.edu.cn

China2 sites

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, 310058

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, 310058

Other trials in China

About this study

Official title: Westlake Aging Cohort

The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.

Read the detailed description

The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.

Keywords
aging, cognition, gut microbiota, multi-omics, brain
Medical subject headings
Cognition Disorders

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cognitive function

    Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians.

    Measured: 48 months

  2. Gut microbiome

    The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified.

    Measured: 48 months

Secondary outcomes (11)

  1. Brain magnetic resonance imaging

    Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants.

    Measured: 48 months

  2. Positron emission tomography

    Assess the brain function and neurological disorders by positron emission tomography (PET).

    Measured: 48 months

  3. Brain images relevant inspections

    Other brain image relevant inspections required for study to measure brain structure and function of participants.

    Measured: 48 months

  4. Electroencephalogram

    Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking.

    Measured: 48 months

  5. Blood biochemical parameters

    Blood biochemical parameters, including glucose and lipids, will be analyzed using an automated biochemical analyzer.

    Measured: 48 months

  6. Serum inflammatory factors

    Detect and assess serum inflammatory factors such as IL-1β, IL-6, and IL-12, in serum from participants.

    Measured: 48 months

  7. Health and behavior monitoring

    Use fitness trackers to record the physiological and behavioral data of participants.

    Measured: 48 months

  8. Sleep data measurement

    Use the polysomnography (PSG) to record the sleep data of participants to evaluate the sleep quality.

    Measured: 48 months

  9. Continuous glucose monitoring

    Use the continuous glucose monitoring (CGM) for dynamic blood glucose recording to determine the glycemic control of participants.

    Measured: 48 months

  10. Environmental measurement

    Use the environmental monitoring device to measure various exposure factors in the participants' living environment.

    Measured: 48 months

  11. Multi-omics data

    Multi omics results of detecting biological samples such as plasma, peripheral blood mononuclear cells (PBMCs), urine, feces, saliva, etc.

    Measured: 48 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2026
  2. Study start1 Jan 2026 (estimated)
  3. Primary completion31 Dec 2030 (estimated)
  4. Study completion31 Dec 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
2,800 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07373444
Sponsor's protocol ID
20251023ZJS001
Status last verified
Jan 2026
First submitted
24 Dec 2025
Last updated
28 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Aging and Cognition Improvement, run by Westlake University at 2 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 28 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ju-Sheng Zheng, PhD (86-0571-86915303, zhengjusheng@westlake.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cognitive function (time frame: 48 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07373444.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Westlake Aging Cohort (WeAC) (NCT07373444) | AzTrials